President Trump on Tuesday told a group of drug company executives gathered for a meeting at the White House that they need to “get prices down.”
“You folks have done a tremendous job but we have to get prices down,” Trump said, according to a pool report.
Trump has been a critic of high drug prices, and has endorsed measures like allowing Medicare to negotiate prices.
But the president also called for reducing regulations to allow for faster approvals of new drugs and to allow drug companies to bring jobs back to the US.
“We’re going to be cutting regulation at a level nobody’s ever seen before,” Trump said in the meeting with executives.
“You can’t get approval for the plant and then you can’t get approval to make the drug, other than that you’re doing fantastic,” he said.
Trump called drug prices “astronomical.”
“US drug companies have produced extraordinary results for our country, but the pricing has been astronomical for our country,” he said.
Still, he also offered to make the Food and Drug Administration’s approval of new drugs “much faster.”
Full Content: The Hill
Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.
Featured News
Federal Judge Orders Google to Open Android App Store Amid Antitrust Pressure
Oct 7, 2024 by
CPI
Federal Judge Greenlights FTC’s Antitrust Lawsuit Against Amazon, Tosses Some State Claims
Oct 7, 2024 by
CPI
Supreme Court Rejects Uber and Lyft’s Appeal in California Gig Worker Suits
Oct 7, 2024 by
CPI
Supreme Court Sidesteps 5-Hour Energy Pricing Case, Allowing Antitrust Claims to Proceed
Oct 7, 2024 by
CPI
Tempur Sealy and Mattress Firm Argue FTC Proceedings Are Unconstitutional in New Suit
Oct 7, 2024 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Refusal to Deal
Sep 27, 2024 by
CPI
Antitrust’s Refusal-to-Deal Doctrine: The Emperor Has No Clothes
Sep 27, 2024 by
Erik Hovenkamp
Why All Antitrust Claims are Refusal to Deal Claims and What that Means for Policy
Sep 27, 2024 by
Ramsi Woodcock
The Aspen Misadventure
Sep 27, 2024 by
Roger Blair & Holly P. Stidham
Refusal to Deal in Antitrust Law: Evolving Jurisprudence and Business Justifications in the Align Technology Case
Sep 27, 2024 by
Timothy Hsieh